StockNews.AI
DRMA
StockNews.AI
203 days

Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment

1. Dermata's XYNGARI™ receives first U.S. patent for acne treatment. 2. Topline results from Phase 3 clinical trial expected by March 2025.

2m saved
Insight
Article

FAQ

Why Bullish?

The issuance of a patent can enhance DRMA's market position and increase investor confidence. Similar past events often led to a positive price reaction.

How important is it?

The article discusses a key milestone for DRMA that could directly influence its valuation and sales potential.

Why Long Term?

The patent and upcoming trial results could establish DRMA's future revenue streams, influencing long-term investor sentiment.

Related Companies

DRMADRMAW
- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ clinical trial in March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy - SAN DIEGO, CA / ACCESS Newswire / January 28, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced issuance by the United States Patent and Trademark Office of a new patent for its XYNGARI™ product candidate for the treatment of acne. The issued patent, entitled "Compositions and methods for the treatment of skin conditions" (U.S. Patent No.

Related News